Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 17 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
Early P 1 (2)
P 1 (4)
P 2 (7)
P 3 (1)

Trial Status

Recruiting6
Active Not Recruiting3
Completed3
Not Yet Recruiting2
Unknown2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT02180867Phase 2Active Not RecruitingPrimary

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT04332874Phase 2Recruiting

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

NCT07548177Phase 2RecruitingPrimary

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

NCT02867592Phase 2Active Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT07297667Phase 1Not Yet RecruitingPrimary

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

NCT06789081Early Phase 1Active Not RecruitingPrimary

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

NCT06625190Phase 1Recruiting

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT03016819Phase 3RecruitingPrimary

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

NCT03967834Not ApplicableRecruiting

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

NCT06827886Early Phase 1CompletedPrimary

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma

NCT04999761Phase 1Recruiting

AB122 Platform Study

NCT06526897Not ApplicableNot Yet Recruiting

Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma

NCT02636725Phase 2CompletedPrimary

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

NCT03623581Phase 2UnknownPrimary

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

NCT03989596Phase 2Unknown

Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas

NCT03880123Phase 1Withdrawn

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

NCT00340353CompletedPrimary

Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research

Showing all 17 trials

Research Network

Activity Timeline